GLOW vs KLOW: the CS-GLW and CS-KLW Blends Compared

Two clear glass vials side by side above a split chromatogram with three resolved peaks on one side and four on the other

The klow peptide and glow peptide searches both point at the same thing: two multi-component research vials that differ from each other by exactly one ingredient. In this catalogue they are the CS-GLW blend and the CS-KLW blend — the blends commonly searched for as “GLOW” and “KLOW”. This is an evidence review of what sits in each vial and what the published literature says about each component, because the literature says nothing at all about either mixture.

What is actually in each vial

ComponentCS-GLW blendCS-KLW blend
GHK-Cu50 mg50 mg
BPC-15710 mg10 mg
TB-50010 mg10 mg
KPV—10 mg
Total peptide content70 mg80 mg
House codeCS-GLW-70CS-KLW-80
Storage−20 °C, desiccated, protect from light−20 °C, desiccated, protect from light

So the whole difference between CS-GLW and CS-KLW is the tripeptide KPV. Everything else — components, proportions, container, storage — is identical. Any comparison of the two is therefore a comparison of one compound's evidence file against nothing.

The blend-evidence problem, stated first

Each of these four compounds has its own published literature. None of that literature studies them together. The catalogue entries for both blends say so directly: the components are studied separately, and the listing summarises each component rather than any combined effect. That is not a disclaimer dressed up as a caveat; it is the actual state of the record. There is no pharmacology of a mixture that no one has characterised as a mixture, and additive reasoning — three in-vitro files plus one more in-vitro file — is not evidence. Read each component on its own terms and stop there.

Component 1: GHK-Cu

The copper(II) complex of glycyl-histidyl-lysine, first reported in human serum by Pickart and Thaler, 1973. The research areas are skin wound healing in animal models, collagen and extracellular-matrix synthesis, topical cosmetic skin research, and gene-expression profiling. The mechanism offered in the reviews is that GHK binds copper(II) and the complex is the active form, with laboratory reports of effects on collagen and glycosaminoglycan synthesis, metalloproteinase activity, and broad transcriptional changes (Pickart et al., 2015; Pickart and Margolina, 2018). How any of that relates to effects in people is not established, and much of the review literature comes from the discoverer's group, which has commercial ties. We go through that file in detail in GHK-Cu research: what the studies actually show.

Component 2: BPC-157

A synthetic 15-amino-acid peptide (a pentadecapeptide) originally described from a protein in gastric juice. It is the most-cited component of both blends and the one where the gap between citation volume and evidence quality is widest. Published research areas are tendon, ligament and muscle injury models, bone healing in animal models, gastrointestinal mucosal protection models, and angiogenesis and nitric-oxide signalling.

The mechanism is not well established. Animal and cell studies have proposed VEGFR2 and nitric-oxide signalling (the Akt–eNOS axis), ERK1/2 and FAK–paxillin pathways, and changes in growth hormone receptor expression in fibroblasts (McGuire et al., 2025). Two structural features of the literature matter more than any individual finding. First, a 2025 systematic review in orthopaedic sports medicine (Vasireddi et al., 2025) included 36 studies, of which 35 were preclinical and one clinical. Second, the great majority of the preclinical record comes from a single research group in Zagreb. Human data are limited to three small pilot reports — for example an intravenous safety pilot (Lee and Burgess, 2025) — with no large controlled trials; a phase 1 volunteer study of an oral formulation is registered as NCT02637284 with no located results. BPC-157 is also listed by WADA as a prohibited non-approved substance (category S0).

Component 3: TB-500

Here the identity question comes before the evidence question. TB-500 is a trade name, not a standardised scientific term. Analytical work on TB-500 products identified an N-acetylated fragment of thymosin beta-4, residues 17–23, Ac-LKKTETQ (Esposito et al., 2012; Ho et al., 2012), although the name is also used loosely for full-length thymosin beta-4 itself.

That distinction carries the whole interpretation. Thymosin beta-4 is a 43-amino-acid actin-sequestering protein whose LKKTETQ region is the central actin-binding site, associated in laboratory studies with cell migration and angiogenesis (Sosne et al., 2010). Whether the short acetylated fragment reproduces the parent protein's behaviour is not well established — a 2024 analytical and in-vitro study noted that TB-500's own biological effects had not been documented (Rahaman et al., 2024). Fragment-specific research is confined to laboratory, animal and anti-doping work, including a single rat tendon-repair model; WADA prohibits thymosin-β4 and derivatives such as TB-500 under category S2. Anyone citing thymosin beta-4 literature in support of the fragment is making an inference the published record does not license.

Component 4: KPV — the only difference between the two blends

KPV is the tripeptide lysine-proline-valine, corresponding to residues 11–13 — the C-terminal end — of alpha-melanocyte-stimulating hormone (Luger and Brzoska, 2007). It has been studied mainly as an anti-inflammatory peptide, which is a different research tradition from the other three: colitis models in mice, inflammatory signalling in intestinal cell lines, oral nanoparticle delivery research (Xiao et al., 2017), and the broader melanocortin-derived anti-inflammatory peptide literature.

Its mechanism is also not well established. Cell studies report uptake by the PepT1 peptide transporter with associated reductions in NF-κB and MAP-kinase inflammatory signalling (Dalmasso et al., 2008), and mouse colitis data suggest the effects are at least partly independent of the melanocortin-1 receptor (Kannengiesser et al., 2008). The evidence ceiling is firm: no human trials were found on ClinicalTrials.gov, and FDA's compounding review states it identified no human exposure data for the substance (FDA bulk drug substances page). Because KPV is a melanocortin fragment, its receptor context overlaps with the melanocortin pharmacology reviewed in our PT-141 literature review.

Reading the comparison honestly

  • Evidence depth. GHK-Cu has the longest in-vitro record; BPC-157 has the largest volume with the narrowest authorship; TB-500 has an identity problem before it has an evidence problem; KPV has the smallest but arguably cleanest preclinical file, with the clearest statement that no human data exist.
  • Research tradition. Three components sit in matrix, repair and migration biology; KPV sits in mucosal inflammation. Adding it does not extend a theme, it introduces a second one.
  • Combined evidence. Zero, for either vial. That is the single most important line in this comparison.

Characterisation and handling

A multi-component vial is harder to document than a single compound, and that is the practical reason to care about the certificate. Reverse-phase HPLC must resolve three peaks for CS-GLW and four for CS-KLW, with retention behaviour consistent for each component; mass spectrometry confirms each expected molecular mass, which is how a short fragment such as Ac-LKKTETQ or the tripeptide KPV is distinguished from a larger parent molecule. Each lot's certificate states the measured purity and identity for that lot. A blend certificate that reports only a single aggregate figure is not telling you what you need to know about a four-component mixture.

Both blends are supplied as lyophilised powder in a glass vial with crimp seal and flip-top cap, stored at −20 °C, desiccated and protected from light — the light protection is driven by the copper complex, the most light-sensitive component present.

Frequently asked questions

What is the difference between the CS-GLW and CS-KLW blends?

One component. CS-KLW contains KPV in addition to the GHK-Cu, BPC-157 and TB-500 found in CS-GLW; the amounts of the shared three are the same in both, and total peptide content is 70 mg against 80 mg.

Is there published research on either blend as a blend?

No. Every published study covers one compound at a time. Both catalogue entries state that the components are studied separately and that the listing summarises each component rather than any combined effect.

Why does the TB-500 identity question matter in a blend?

Because the name is used both for an N-acetylated thymosin beta-4 fragment (Ac-LKKTETQ) and loosely for the full-length 43-amino-acid protein. Those are different molecules with different masses, so the mass-spectrometry data on the lot certificate is what tells you which one is in the vial.

Can the components be sourced separately instead?

Yes — GHK-Cu, BPC-157, TB-500 and KPV are all catalogued as single compounds, each with its own lot certificate. Separate vials also mean separate, unambiguous characterisation data per compound.

See it in the catalogue: CS-KLW blend.

For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.

California Standard Peptides

Your cart

0 items · free shipping over $200.00

Your cart is empty.

Buy 2 of a vial and save 10%, 3 and save 15%. Research sets are 15% off, and shipping is free over $200.00.

First order

20% off your first order.

Join the list for first word on new lots, restocks and member pricing. Your code arrives by email and applies by itself at checkout.

One code per email, for your first order. By signing up you agree to get emails from us. Unsubscribe anytime.

For laboratory research use only. 21+.